Description
The ophthalmic formulation Pilocar Eye Drop 1% contains Pilocarpine at a strength of 1% which stands as the major miotic agent. The medical eye solution produced by FDC Ltd is intended specifically for glaucoma treatment alongside other eye medical issues by controlling IOP. The eye drop Pilocar Eye Drop 1% helps protect vision and eyes from additional harm because it lowers elevated intraocular pressure.
How Pilocar Eye Drop 1% Works
Pilocar Eye Drop 1% works by increasing the rate at which the fluid in the eye, known as aqueous humor, drains out of the eye reducing intraocular pressure. The active component of the eye drop solution is Pilocarpine which has properties of making the pupils to contract hence allowing the fluid to drain thus reducing pressure.
Key Characteristics
Active Ingredient: Pilocarpine (1%)
Dosage Form: Eye Drops
Indications: Glaucoma, Ocular Hypertension, and Other Eye Conditions
Manufacturer: FDC Ltd
Advantages of Pilocar Eye Drop 1%
- Reduces intraocular pressure to the optimal level thus avoiding damage to the optic nerve.
- Regarding the advantages, chronic use may help in the prevention of further deterioration of eyesight in glaucoma patients.
- Operates swiftly to reduce the pressure thus improving the comfort of the eyes.
- Frequently used in ophthalmology for the treatment of multiple conditions.
Possible Side Effects
As Pilocar Eye Drop 1% is generally good at tolerating, serious side effects that may occur include:
- Blurred Vision
- Eye Irritation or Redness
- Headache
- Temporary Stinging Sensation
Conclusion
Pilocar Eye Drop 1% is a known medication for glaucoma and similar ailments as it assists in controlling intraocular pressure and various other issues. Long-term supportive treatment provided by an opthamologist helps users protect their vision while stopping potential optic nerve damage. It is essential to receive ophthalmologist consultation beforehand to determine if eye drops are suitable for a person’s experienced condition.
Reviews
There are no reviews yet.